Jump to content

Template:Sodium-glucose transporter modulators

From Wikipedia, the free encyclopedia

This is the current revision of this page, as edited by A455bcd9 (talk | contribs) at 13:01, 26 January 2024 (Only 10% of canagliflozin's effect comes from SGLT-1 inhibition and it is largely described in the literature as an SGLT2 inhibitor while sotagliflozin is described as the first dual SGLT1/2 inhibitor. Better to be consistent with RS here (although yes, canagliflozin also inhibits a bit SGLT1, but dapagliflozin also does it fwiw).). The present address (URL) is a permanent link to this version.

(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

This template's initial visibility currently defaults to autocollapse, meaning that if there is another collapsible item on the page (a navbox, sidebar, or table with the collapsible attribute), it is hidden apart from its title bar; if not, it is fully visible.

To change this template's initial visibility, the |state= parameter may be used:

  • {{Sodium-glucose transporter modulators|state=collapsed}} will show the template collapsed, i.e. hidden apart from its title bar.
  • {{Sodium-glucose transporter modulators|state=expanded}} will show the template expanded, i.e. fully visible.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Template:Sodium-glucose_transporter_modulators&oldid=1199216191"